Trastuzumab interactions
Full monograph for TrastuzumabCheck it against another medicine
Medicines
46 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Daunorubicin | Major | Synergy | The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline… | 5 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Doxorubicin Hydrochloride | Major | Synergy | The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline… | 5 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Major | Synergy | The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline… | 5 sources — open the full entry |
| Epirubicin Hydrochloride | Major | Synergy | The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Idarubicin Hydrochloride | Major | Synergy | The use of trastuzumab and anthracyclines in combination has been associated with a high risk of cardiotoxicity. Trastuzumab and agents in the anthracycline… | 5 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Ophthalmic) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Denosumab | Moderate | Synergy | Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the… | 2 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Synergy | Coadministration of chloramphenicol with other agents that can cause bone marrow depression or aplastic anemia may increase the risk and/or severity of… | 8 sources — open the full entry |
| Diphtheria + Tetanus + Pertussis + Hepatitis B + Polio + HIB | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Diroximel Fumarate | Moderate | Synergy | The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may… | 1 sources — open the full entry |
| Filgrastim | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 4 sources — open the full entry |
| Ganciclovir | Moderate | Synergy | The use of ganciclovir with other potentially myelotoxic and/or nephrotoxic agents may increase the risk and severity of hematologic toxicity and/or… | 7 sources — open the full entry |
| Hepatitis B Vaccine [rDNA] | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Inactivated Hepatitis A vaccine | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Lactobacillus Rhamnosus GG | Moderate | Others | Probiotic use during immunosuppressant or intense antineoplastic therapy may theoretically increase the risk of infections from the live microorganisms… | 11 sources — open the full entry |
| Lamivudine + Zidovudine | Moderate | Synergy | Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity… | 8 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Moderate | Synergy | Coadministration of zidovudine with other bone marrow depressive or cytotoxic agents may increase the risk and/or severity of zidovudine hematologic toxicity… | 8 sources — open the full entry |
| Lenograstim | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 4 sources — open the full entry |
| Nab-Paclitaxel [Nanoparticle Albumin-Bound Paclitaxel] | Moderate | Metabolism | Non-human studies have demonstrated that paclitaxel can significantly increase the serum levels and decrease the clearance of trastuzumab. The mechanism is… | 10 sources — open the full entry |
| Niraparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome… | 1 sources — open the full entry |
| Ocrelizumab | Moderate | Synergy | The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of… | 1 sources — open the full entry |
| Olaparib | Moderate | Synergy | Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with olaparib. Myelodysplastic syndrome… | 4 sources — open the full entry |
| Paclitaxel | Moderate | Metabolism | Non-human studies have demonstrated that paclitaxel can significantly increase the serum levels and decrease the clearance of trastuzumab. The mechanism is… | 10 sources — open the full entry |
| Pegfilgrastim [Pegylated Filgrastim] | Moderate | Antagonism | INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given… | 2 sources — open the full entry |
| Roflumilast (Tablet) | Moderate | Synergy | The concomitant use of roflumilast with immunosuppressive agents has not been adequately studied. Specifically, roflumilast and its active metabolite… | 5 sources — open the full entry |
| Topotecan | Moderate | Synergy | The use of topotecan with other cytotoxic agents is likely to result in greater myelosuppression due to additive or synergistic pharmacologic effects. Severe… | 1 sources — open the full entry |
| Typhoid conjugate vaccine | Moderate | Antagonism | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 10 sources — open the full entry |
| Typhoid polysaccharide vaccine | Moderate | Others | The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a… | 11 sources — open the full entry |
| Warfarin Sodium | Moderate | Others | Trastuzumab may potentiate the hypoprothrombinemic effect of warfarin, although data are limited and the mechanism is unknown. | 39 sources — open the full entry |
This source documents no food, condition or duplication entries for Trastuzumab.